Drug intelligence / Profile preview

SLIM2403

Development stage: Preclinical
Lead developer: Samik Pharm
Modality: Small Molecules

Overview

SLIM2403 is a small molecule therapeutic candidate being developed by Samik Pharmaceutical for the treatment of obesity. It is classified as an "improved new drug" (개량신약) within the South Korean regulatory framework, which typically indicates a modification of an existing active pharmaceutical ingredient—such as a new salt, formulation, or derivative—intended to provide clinical benefits like enhanced efficacy, improved safety profiles, or better patient compliance. As of 2024, the program is in the preclinical stage of development.

Beyond the preview

Go deeper on SLIM2403.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLIM2403.

Explore the full profile